A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease

The authors aimed to determine whether the somatostatin analogue lanreotide could slow the decline of glomerular filtration rate (GFR) in adults with stage 2/3 autosomal dominant polycystic kidney disease (ADPKD) over three years. The study found that lanreotide did not significantly affect GFR decline compared to placebo, although there was an exploratory signal in creatinine-based estimates that was not corroborated by other measures. Additionally, lanreotide was associated with a higher incidence of gastrointestinal adverse events and hypoglycemia, highlighting the need for careful monitoring in this patient population.